Key Event: US FDA Approval
Cipla Limited received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder). The approval covers all three dosage strengths: 100/50 mcg, 250/50 mcg, and 500/50 mcg.
Product Details
The approved product is a therapeutically equivalent version of Advair Diskus®, a combination therapy indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). According to IQVIA data referenced in the disclosure, the U.S. market for fluticasone propionate and salmeterol inhalation powder is approximately $908 million.
Manufacturing Significance
This approval represents Cipla's first dry powder inhaler (DPI) approval from its U.S.-based manufacturing network, specifically mentioned as coming from their New York facility.
Launch Timeline
The product is expected to be launched in Q2 of FY 2026-27 (July-September 2026 quarter) in the United States market.
Management Commentary
Achin Gupta, Managing Director & Global CEO of Cipla Limited, stated that this approval reinforces the company's commitment to expanding access to complex therapies in the U.S. and highlights their strength in developing and scaling sophisticated inhalation products.
Marc Falkin, Chief Executive Officer of Cipla North America, added that this marks their first dry powder inhaler from their New York facility and reflects targeted investments in building differentiated inhalation manufacturing capabilities in the U.S.
Company Background Context
The disclosure includes that Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Jun'26), 2nd largest in the pharma prescription market in South Africa (IQVIA MAT May'26), and 2nd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Jun'26).